Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
P
00

Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

Aug 4, 2026

Pathos AI has expanded its oncology pipeline by securing two major breast cancer drug licensing deals. The company entered a global licensing agreement with Alphamab Oncology for JSKN016, a bispecific antibody-drug conjugate, in a deal valued at up to $2.093 billion, including a $125 million upfront payment. Additionally, Pathos AI partnered with AstraZeneca to clinically develop AZD4241, a preclinical estrogen receptor degrader. Pathos AI will leverage its proprietary Foundry AI platform to optimize clinical trials and patient selection for both therapies.

Featured stories

View more in Cancer & Oncology

LangChain raises $300 million at $3 billion valuation

Nov 12, 2026 · 2 sources

Q-CTRL raises $290 million Series C at over $1 billion valuation for quantum software

Nov 12, 2026 · 3 sources

Norwest raises $4 billion fund focused on AI investments

Nov 12, 2026 · 2 sources

Fractile raises $720 million Series C at $7 billion valuation for AI chips

Nov 11, 2026 · 3 sources

Story comments

Loading comments…

Related Projects

Pathos AIAstraZeneca

Topics

Cancer & OncologyCancer TypesCancer Treatment & TherapiesAI in drug discoveryDrug Policy, Pricing & ApprovalVenture capital fundingOncology

Featured stories

View more in Cancer & Oncology

LangChain raises $300 million at $3 billion valuation

Nov 12, 2026 · 2 sources

Q-CTRL raises $290 million Series C at over $1 billion valuation for quantum software

Nov 12, 2026 · 3 sources

Norwest raises $4 billion fund focused on AI investments

Nov 12, 2026 · 2 sources

Fractile raises $720 million Series C at $7 billion valuation for AI chips

Nov 11, 2026 · 3 sources